Breakthrough Biodegradable Capsule Aids Hemophilia Treatment
|
By Daniel Beris Posted on 13 Dec 2016 |
|
Image: A hemophilia capsule only degrades in the small intestine (Photo courtesy of UT Austin).
A new study describes how an innovative biodegradable capsule that uses hydrophilic carriers for oral delivery of hematological factor IX (hFIX) can treat hemophilia B.
Developed by researchers at the University of Texas (UT; Austin, USA), the oral delivery system is based on a pH-responsive polymer hydrogel microcarrier system that carries the prophylactic hFIX particles. The poly (methacrylic acid)-grafted-poly(ethylene glycol) [P(MAA-g-EG)] polymer, synthesized using ultraviolet (UV) polymerization, is subsequently joined with an enzymatically degradable peptide crosslinking agent that allows for site-specific degradation (by trypsin) in the small intestine.
As it moves through the body, the particle-containing capsule resists the major gastric enzyme in order to remain intact while in the stomach, protecting the encapsulated drug. When in the small intestine, the capsule begins to swell with the increase in pH, and is subsequently degraded by the minor intestinal enzyme, slowly releasing the drug over time. In study models, the system successfully transported hFIX, and was able to deliver adequate levels of the drug to the target site in the small intestine. The study was published on November 15, 2016, in the International Journal of Pharmaceutics.
“While an oral delivery platform will be beneficial to all hemophilia B patients, patients in developing countries will benefit the most,” said lead author Sarena Horava, PhD, of the UT Cockrell School of Engineering. “In many developing countries, the median life expectancy for hemophilia patients is 11 years due to the lack of access to treatment, but our new oral delivery of factor IX can now overcome these issues and improve the worldwide use of this therapy.”
Hemophilia B is a blood clotting disorder caused by a mutation of the factor IX gene, leading to a deficiency of factor IX. It is the second-most common form of hemophilia, and is sometimes called Christmas disease, after Stephen Christmas, the first patient described with the affliction. Presentation of hemophilia B is consistent with easy bruising, urinary tract bleed, and nosebleeds. Current protein replacement therapies rely on intravenous (IV) injections and infusions.
Related Links:
University of Texas
Developed by researchers at the University of Texas (UT; Austin, USA), the oral delivery system is based on a pH-responsive polymer hydrogel microcarrier system that carries the prophylactic hFIX particles. The poly (methacrylic acid)-grafted-poly(ethylene glycol) [P(MAA-g-EG)] polymer, synthesized using ultraviolet (UV) polymerization, is subsequently joined with an enzymatically degradable peptide crosslinking agent that allows for site-specific degradation (by trypsin) in the small intestine.
As it moves through the body, the particle-containing capsule resists the major gastric enzyme in order to remain intact while in the stomach, protecting the encapsulated drug. When in the small intestine, the capsule begins to swell with the increase in pH, and is subsequently degraded by the minor intestinal enzyme, slowly releasing the drug over time. In study models, the system successfully transported hFIX, and was able to deliver adequate levels of the drug to the target site in the small intestine. The study was published on November 15, 2016, in the International Journal of Pharmaceutics.
“While an oral delivery platform will be beneficial to all hemophilia B patients, patients in developing countries will benefit the most,” said lead author Sarena Horava, PhD, of the UT Cockrell School of Engineering. “In many developing countries, the median life expectancy for hemophilia patients is 11 years due to the lack of access to treatment, but our new oral delivery of factor IX can now overcome these issues and improve the worldwide use of this therapy.”
Hemophilia B is a blood clotting disorder caused by a mutation of the factor IX gene, leading to a deficiency of factor IX. It is the second-most common form of hemophilia, and is sometimes called Christmas disease, after Stephen Christmas, the first patient described with the affliction. Presentation of hemophilia B is consistent with easy bruising, urinary tract bleed, and nosebleeds. Current protein replacement therapies rely on intravenous (IV) injections and infusions.
Related Links:
University of Texas
Gold Member
12-Channel ECG
CM1200B
Pediatric Mask
Respire SOFT
Immobilization System
Cranial 4Pi Immobilization
Latest Critical Care News
- Octopus-Inspired Patch Improves Adhesion for Transdermal Drug Delivery
- Multimodal AI System Tracks Early Warning Signs of Mental Health Crisis
- Self-Folding Paper Sensor Conforms to Body Without Straps or Adhesives
- Patch-Based Therapy Promotes Myelin Repair in Multiple Sclerosis
- Rapid EHR Surveillance Helps Protect High-Risk Patients During Heat Waves
- Remote Cardiac Device Monitoring System Shows Safety and Cost Benefits
- Ambulatory ECG Monitor Improves Arrhythmia Detection in Syncope
- New Prediction Tool Supports Confident Prescribing of Heart Failure Medicines
- Machine Learning Models Identify Higher-Risk Pregnancies Earlier in Care
- Wearable Hormone Monitor Enables At-Home Detection of Primary Aldosteronism
- Contactless AI Tool Detects Hypertension and Diabetes from Facial Video
- AI Tool Predicts Bladder Cancer from Electronic Health Records
- Personalized Neuromodulation System Receives FDA Clearance for PTSD Treatment
- New Multimodal Framework Targets Debilitating Form of Heart Failure
- Telehealth-Enabled Paramedic Program Supports Post-Discharge Heart Failure Care
- AI Software Update Boosts Image Quality and Workflow for Portable MRI System
Channels
Artificial Intelligence
view channel
AI Tools Show Potential to Detect Subtle Signs of Interval Breast Cancer
Interval breast cancers, diagnosed after a negative screening mammogram and before the next scheduled exam, remain an important measure of screening performance and are often more aggressive.... Read more
AI Framework Aims to Turn Medical Care from Reactive to Preventive
Health systems face rising burdens from aging populations, chronic disease, and workforce shortages. Medical artificial intelligence (AI) remains concentrated in diagnosis and decision support, leaving... Read more
Surgical Techniques
view channel
New Transvaginal Transducer Improves Imaging for Gynecology and Early Obstetrics
Transvaginal ultrasound is central to gynecology and early obstetrics, where clinicians must balance deep tissue penetration with high-resolution imaging. Switching probes to achieve this balance can interrupt... Read more
Mobile 3-in-1 Imaging System Advances Intraoperative Navigation
Globus Medical’s Excelsius3D intelligent 3-in-1 imaging system has received the CE Mark for commercial sale in the European Union and the United Kingdom. The addition of Excelsius3D expands the company’s... Read more
Patient Care
view channel
Virtual Reality Helps Claustrophobic Patients Complete Cardiac PET/CT Scans
Anxiety and claustrophobia—intense fear of confined spaces—often prevent patients from completing cardiac positron emission tomography/computed tomography (PET/CT). Aborted scans delay diagnosis, consume... Read more
Weighted Blankets Reduce Anxiety in Hospitalized Adults
Anxiety is common among hospitalized adults and can impair recovery, disrupt sleep, and worsen mental health. Although clinicians often use nonpharmacologic strategies, bedside options that act quickly... Read more
Medical Imaging
view channel
Automated Platform Converts Super-Resolution Ultrasound into Vascular Biomarkers
Microvascular dysfunction, an early marker of glaucoma, cancer, and other systemic illnesses, often precedes overt clinical signs yet remains difficult to quantify deep in tissue. Super-resolution ultrasound... Read more
Targeted PET/MRI Improves Detection and Preoperative Mapping of Endometriosis
Endometriosis is a chronic inflammatory condition in which endometrial-like tissue grows outside the uterus, causing pelvic pain, infertility, and reduced quality of life. Conventional imaging can underestimate... Read more
Health IT
view channel
Registry-Driven Digital Outreach Boosts Use of Heart Failure Medicines
Heart failure affects more than 64 million people worldwide and is linked to high mortality, reduced quality of life, and heavy healthcare use. Although sodium-glucose cotransporter 2 inhibitors are proven... Read more
Nurse-Coordinated Care Model Improves Heart Failure Outcomes
Heart failure imposes heavy mortality, morbidity, and cost burdens worldwide, yet proven therapies remain underused in routine practice. This inadequate uptake contributes to preventable hospitalizations... Read more
Point of Care
view channel
Microneedle Patch Enables At-Home Monitoring of Acute Kidney Injury
Kidney disease is often silent in its early stages, making timely detection difficult outside clinical settings. Early biomarkers such as neutrophil gelatinase–associated lipocalin can require blood draws... Read more
Ultrathin Metasurface Could Bring Quantitative Phase Imaging to Portable Devices
Point-of-care imaging often depends on bulky optical systems that have difficulty visualizing nearly transparent cells and tissues without staining. These limitations can slow diagnosis and restrict use... Read more
Business
view channel
Smartphone-Integrated Epinephrine Auto-Injector Concept Wins Red Dot Design Award
Severe allergic reactions can escalate rapidly and require prompt epinephrine, yet many at-risk patients do not consistently carry their auto-injector. With food allergies affecting an estimated 220 million... Read more
